Risk of QTc prolongation due to combination of ziprasidone and quetiapine;QTc-Zeitverlängerung unter Ziprasidon in Kombination mit Quetiapin

Psychiatrische Praxis, Supplement

Volumn 31, Issue 1, 2004, Pages

  Minov, Christo ^a  

^a Bezirkskrankenhaus Augsburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE; ZIPRASIDONE;

AGED; CASE REPORT; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG SAFETY; ELECTROCARDIOGRAM; EXTRASYSTOLE; HEART ARRHYTHMIA; HUMAN; MALE; QT INTERVAL; QT PROLONGATION; RISK; SCHIZOPHRENIA; TREATMENT WITHDRAWAL;

EID: 11144333681     PISSN: 16118332     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828458     Document Type: Conference Paper

References (13)

1. Möller HJ. Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 2000; 71: 329-344
2. Zorn SH, Schmidt AW, Lebel AW et al. The unique receptor binding profile of ziprasidone may contribute to both ist antipsychotic efficacy and reduced weight gain. Washington: Ann Meeting Am Psychiatr Assoc, 1998
3. Daniel DG, Copeland LF. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Investig Drugs 2000; 9: 819-828
4. Davis R, Markham A. Ziprasidone. CNS Drugs 1997; 8: 153-159
5. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003; 23: 229-232
6. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38: 389-430
7. Prakash C, Kamel A, Cui D. Identification of the human liver cytochro me P450 isoform(s) responsible for the formation of the primari metabolites of ziprasidone and prediction of possibile drug interactions. Br J Clin Pharmacol 2000; 49 (Suppl 1): 35-42
8. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28: 99-112
9. Glassman AH, Bigger JT jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782
10. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625-1633
11. Haverkamp W, Haverkamp F, Breithardt G. Medikamentenbedingte QT-Verlängerung und Torsade de pointes. Dtsch Ärztebl 2002; 99: 1972-1979
12. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003; 17: 423-430
13. Food and drug Administration Center for Drug Evaluation Research. Transcript of FDA Psychopharmacological Drugs Advisory Committee Hearing, July 19, 2000